What's the success rate of tigecycline in infections?

Tigecycline’s “success rate” depends a lot on which infection, how sick the patient is, and the study design (and even how “success” is defined—usually clinical response at a test-of-cure time point).

That said, here are typical ranges from major clinical trials for tigecycline in serious bacterial infections (adults), using the common endpoints of clinical response at the test-of-cure.

Common infection types (approximate)

• Complicated skin and skin structure infections (cSSSI)

  • Clinical success is often around ~70–80%.

• Complicated intra‑abdominal infections (cIAI)

  • Clinical success is often around ~70% (commonly ~60–75% depending on subgroup and comparator).

• Hospital-acquired pneumonia / ventilator-associated pneumonia (HAP/VAP)

  • This is where tigecycline historically performed worse in some trials.
  • Clinical success/mortality outcomes were concerning; overall effectiveness was not as strong as comparators in many studies.
  • A simple “success rate” number is less representative here because the safety signal (notably higher mortality vs some comparators in earlier studies) affected interpretation.

Important caveats (why the answer varies)

• Resistance patterns and whether the pathogen is tigecycline-susceptible matter a lot.
• Source control (drainage/surgery for IAI, wound management for cSSSI) strongly affects success.
• Trials often exclude or treat differently severe bacteremia, which can skew real-world expectations.
• Tigecycline dosing strategies and local practice also affect outcomes.

Quick question so I can give you a tighter number

Which infection are you asking about—cIAI, cSSSI, pneumonia (HAP/VAP), or something else (e.g., bacteremia, osteomyelitis, MDR infections like CRE/Acinetobacter, etc.)?
If you tell me the infection type (and ideally whether it’s ICU/severe or bloodstream-involved), I can narrow to the most relevant trial data and range.